ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.12 -0.19 (-4.41%)
At close: Oct 1, 2026 · 4:00 PM EDT

ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2020 - 2026)

Updated

ARS Pharmaceuticals (SPRY) recorded Cash from Financing Activities of $3.2 million in Q2 2026, up 18.5% from $2.7 million a year earlier.

Analysis

ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2020 - 2026) Analysis & Trends

On a TTM basis, ARS Pharmaceuticals' Cash from Financing Activities came in at $104.53 million as of Jun 30, 2026, up 39.3% year-over-year; for FY2025, it was $104.6 million, up 44.5% from FY2024.

  • Annual Cash from Financing Activities has a five-year compound annual growth rate of -23.9% (FY2020 to FY2025).
  • Across earlier years, Cash from Financing Activities came in at $72.4 million in FY2024 (+949.4%), $6.9 million in FY2023 (-96.4%), $190.73 million in FY2022 (+258.8%) and $53.16 million in FY2021 (-87.0%).
  • Quarterly Cash from Financing Activities has ranged from -$1.56 million in Q3 2022 to $193.82 million in Q4 2022 over the past five years.
  • On a year-over-year basis, Cash from Financing Activities rose in three of the last six quarters, with growth averaging 65.3%.
  • Peak year-over-year performance for Cash from Financing Activities in the last five years was growth of 394.9% in Q2 2025, against a decline of 99.9% in Q3 2021 at the low end.
  • Per Business Quant, the preceding three quarters came in at $159,000 (Q1 2026), $1.13 million (Q4 2025) and $100.05 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 ARS Pharmaceuticals 428.58 Mn 284.78 Mn 20.81 Mn 3.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.20 Mn
Mar 31, 2026 159,000.00
Dec 31, 2025 1.13 Mn
Sep 30, 2025 100.05 Mn
Jun 30, 2025 2.70 Mn
Mar 31, 2025 725,000.00
Dec 31, 2024 70.92 Mn
Sep 30, 2024 680,000.00
Jun 30, 2024 545,000.00
Mar 31, 2024 258,000.00
Dec 31, 2023 1.81 Mn
Sep 30, 2023 921,000.00
Jun 30, 2023 2.85 Mn
Mar 31, 2023 1.32 Mn
Dec 31, 2022 193.82 Mn
Sep 30, 2022 -1.56 Mn
Jun 30, 2022 -623,000.00
Mar 31, 2022 -908,000.00
Dec 31, 2021 52.82 Mn
Sep 30, 2021 148,000.00
API Access

ARS Pharmaceuticals Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=SPRY&period=max&api_key=YOUR_API_KEY